Tamibarotene - Syros Pharmaceuticals

Drug Profile

Tamibarotene - Syros Pharmaceuticals

Alternative Names: AM-80; Amnoid; Amnolake; INNO-507; NSC-608000; OMS0728; Retinobenzoic acid; RR-110; SY-1425; Tamibaro; Tamibarotene; TM-411; TOS-80T; Z-208

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shionogi
  • Developer Childrens Hospital Los Angeles; CytRx Corporation; GNI; Nippon Shinyaku; Ohara Pharmaceutical; Syros Pharmaceuticals; TMRC Co. Ltd; Toko Pharmaceutical Industrial; Zeria
  • Class Antineoplastics; Benzoates; Retinoids; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Retinoic acid receptor alpha agonists; Retinoic acid receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute promyelocytic leukaemia; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute promyelocytic leukaemia
  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Preclinical Breast cancer; Neutropenia
  • No development reported Solid tumours
  • Discontinued Crohn's disease; Liver cancer; Non-small cell lung cancer; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for phase-I development in Solid-tumours(In adolescents, In children, In infants, Second-line therapy or greater) in Japan (PO)
  • 22 Jan 2018 Syros Pharmaceuticals has two patent protection for tamibarotene covering method of diagnosis and treatment of Acute myeloid leukaemia and Myelodysplastic syndrome in USA
  • 02 Jan 2018 Syros Pharmaceuticals enters into a clinical supply agreement with Janssen to evaluate tamibarotene in combination with daratumumab in a phase II clinical trial in patients with Acute myeloid leukaemia and Myelodysplastic syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top